Last reviewed 2026-05-22 · How we verify

Hypoestoxide

University of Ibadan · Phase 1 active Small molecule ✓ Verified May 2026

Hypoestoxide is a Small molecule drug developed by University of Ibadan. It is currently in Phase 1 development. Also known as: PECKO-D forte.

Hypoestoxide is being studied as a potential treatment for Parkinson's Disease in a clinical trial. The trial, NCT04858074, is investigating the effect of 100% Hypoestes rosea powder in Parkinson's Disease using ActiGraph wearable devices.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Hypoestoxide
Also known as	PECKO-D forte
Sponsor	University of Ibadan
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hypoestoxide CI brief — competitive landscape report
Hypoestoxide updates RSS · CI watch RSS
University of Ibadan portfolio CI

Frequently asked questions about Hypoestoxide

What is Hypoestoxide?

Hypoestoxide is a Small molecule drug developed by University of Ibadan.

Who makes Hypoestoxide?

Hypoestoxide is developed by University of Ibadan (see full University of Ibadan pipeline at /company/university-of-ibadan).

Is Hypoestoxide also known as anything else?

Hypoestoxide is also known as PECKO-D forte.

What development phase is Hypoestoxide in?

Hypoestoxide is in Phase 1.

Manufacturer: University of Ibadan — full pipeline
Therapeutic area: All drugs in Other
Also known as: PECKO-D forte

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing